Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
18
PHAT Quote, Financials, Valuation and Earnings
Last price:
$7.49
Seasonality move
:
-9.47%
Day range:
$7.21 - $7.72
52-week range:
$6.07 - $19.71
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
17.05x
P/B ratio:
--
Volume:
401.7K
Avg. volume:
1.5M
1-year change:
-16.76%
Market cap:
$512.8M
Revenue:
$682K
EPS (TTM):
-$5.75
Analysts' Opinion
-
Consensus RatingPhathom Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $22.00, Phathom Pharmaceuticals has an estimated upside of 231.43% from its current price of $7.50.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.00 representing 100% downside risk from its current price of $7.50.
Fair Value
-
According to the consensus of 6 analysts, Phathom Pharmaceuticals has 231.43% upside to fair value with a price target of $22.00 per share.
PHAT vs. S&P 500
-
Over the past 5 trading days, Phathom Pharmaceuticals has underperformed the S&P 500 by -12.96% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Phathom Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Phathom Pharmaceuticals has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Phathom Pharmaceuticals reported revenues of $16.4M.
Earnings Growth
-
Phathom Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Phathom Pharmaceuticals reported earnings per share of -$1.32.
Enterprise value:
353.9M
EV / Invested capital:
-31.09x
Price / LTM sales:
17.05x
EV / EBIT:
--
EV / Revenue:
13.47x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.43x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$21.9M
Return On Assets:
-91.94%
Net Income Margin (TTM):
-1292.14%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-432.95%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $26.3M | -- | $16.4M | |
| Gross Profit | -- | -- | $21.9M | -- | $14M | |
| Operating Income | -$158.8M | -$144.1M | -$287.9M | -$35.7M | -$70.8M | |
| EBITDA | -$157.4M | -$138M | -$272.2M | -$33M | -$66.9M | |
| Diluted EPS | -$4.67 | -$3.82 | -$5.75 | -$0.76 | -$1.32 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $227.2M | $225.3M | $197.8M | $226.7M | $373.8M | |
| Total Assets | $230.9M | $228.4M | $201.9M | $237M | $387M | |
| Current Liabilities | $27.7M | $27.8M | $22.9M | $24M | $65.3M | |
| Total Liabilities | $74.5M | $124.9M | $228.4M | $254.8M | $574.2M | |
| Total Equity | $156.4M | $103.5M | -$26.4M | -$17.8M | -$187.1M | |
| Total Debt | -- | -- | -- | -- | $175.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$146.8M | -$134.8M | -$247.1M | -$31.9M | -$63.6M | |
| Cash From Investing | -$729K | -$1.6M | -$605K | -$939K | -$44K | |
| Cash From Financing | $120.2M | $155.6M | $368.7M | $13K | $122.1M | |
| Free Cash Flow | -$147.5M | -$136.4M | -$247.7M | -$32.9M | -$63.6M | |
PHAT
Sector
Market Cap
$512.8M
$45.6M
Price % of 52-Week High
38.05%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
-10.3%
-0.74%
1-Year Price Total Return
-16.76%
-31.35%
Beta (5-Year)
0.562
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$7.85
200-day SMA
Sell
Level
$12.08
Bollinger Bands (100)
Sell
Level
9.88 - 17.7
Chaikin Money Flow
Sell
Level
-28.1M
20-day SMA
Sell
Level
$8.41
Relative Strength Index (RSI14)
Sell
Level
31.11
ADX Line
Sell
Level
18.61
Williams %R
Buy
Level
-82.971
50-day SMA
Sell
Level
$11.91
MACD (12, 26)
Sell
Level
-1.10
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Sell
Level
-21.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.7203)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Stock Forecast FAQ
In the current month, PHAT has received 5 Buy ratings 1 Hold ratings, and 0 Sell ratings. The PHAT average analyst price target in the past 3 months is $22.00.
-
Where Will Phathom Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Phathom Pharmaceuticals share price will rise to $22.00 per share over the next 12 months.
-
What Do Analysts Say About Phathom Pharmaceuticals?
Analysts are divided on their view about Phathom Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Phathom Pharmaceuticals is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is Phathom Pharmaceuticals's Price Target?
The price target for Phathom Pharmaceuticals over the next 1-year time period is forecast to be $22.00 according to 6 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is PHAT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Phathom Pharmaceuticals is a Buy. 5 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PHAT?
You can purchase shares of Phathom Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Phathom Pharmaceuticals shares.
-
What Is The Phathom Pharmaceuticals Share Price Today?
Phathom Pharmaceuticals was last trading at $7.49 per share. This represents the most recent stock quote for Phathom Pharmaceuticals. Yesterday, Phathom Pharmaceuticals closed at $7.50 per share.
-
How To Buy Phathom Pharmaceuticals Stock Online?
In order to purchase Phathom Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
